Cystic Fibrosis News Today Weekly Digest

Cystic Fibrosis Weekly Update Contents: Trikafta’s Approval the Outcome of ’20-year Journey That Started with a Dream,’ Says Vertex CEO Jeffrey Leiden What to Do When Everyone Dies The Present Realizes the Past Through Travel Alaxia Joins iABC to Speed Development of ALX-009, Potential Antibiotic for Resistant Lung Infections Trikafta’s Approval the Outcome of ’20-year Journey That Started with a Dream,’ Says Vertex CEO Jeffrey Leiden Oct 30, 2019 07:30 am | Patricia Inacio, PhD When Vertex Pharmaceuticals’ cystic fibrosis (CF) therapy Trikafta was approved recently by the U.S. Food and Drug Administration, it was a dream come true for Jeffrey Leiden, Vertex’s chairman, president and CEO. The therapy, which treats the most common mutation in CF patients (the F508del mutation in the CFTR gene) was considered a dream 20 years ago — a dream “that you […] The post Trikafta’s Approval the Outcome of ’20-year Journey That Started with a Dream,’ Says Vertex CEO Jeffrey Leiden appeared first on Cystic Fibrosis News Today. Read More What to Do When Everyone Dies Oct 29, 2019 03:00 pm | Bailey Vincent Two of my friends are dead. And I’m scared. Recently, I lost two friends on the same day. One was in love with a dear friend of mine — he has a milder form of cystic fibrosis, and they successfully loved and lived for years. The other I texted nearly every day. She was a […] The post What to Do When Everyone Dies appeared first on Cystic Fibrosis News Today. Read More The Present Realizes the Past Through Travel Oct 29, 2019 09:00 am | Brad Dell In my senior year of college, I wanted to be just like Dad. He’s a courageous traveler who has filled many passports and has eaten all sorts of weird foods. The problem was that traveling kind of scared me. No, it really scared me. It seemed like every plane ride resulted in me catching an […] The post The Present Realizes the Past Through Travel appeared first on Cystic Fibrosis News Today. Read More Alaxia Joins iABC to Speed Development of ALX-009, Potential Antibiotic for Resistant Lung Infections Oct 29, 2019 07:00 am | Ana Pena, PhD Alaxia has joined the European consortium iABC to accelerate the development of ALX-009, an investigational inhaled antibiotic for multi-drug resistant lung infections in people with cystic fibrosis (CF). Under the partnership, Alaxia will have support for setting up clinical trials and recruiting patients, and will gain access to expertise on antimicrobial agents from iABC members. […] The post Alaxia Joins iABC to Speed Development of ALX-009, Potential Antibiotic for Resistant Lung Infections appeared first on Cystic Fibrosis News Today. Read More Recent News Giving My Anxiety a Name Vertex, NHS England Reach Agreement on Pricing and Public Availability of CF Treatments CF Patients Voice Hopes and Expectations for Trikafta in Instagram Poll CF Mutation Carriers Have Increased Risk for Gastrointestinal Problems, Large-scale Study Finds Cystic Fibrosis Foundation Applauds FDA Approval of Trikafta